Published :
Tables : 44
Figures : 44
Category : Healthcare
No. of Pages : 232
Report Code : HC-U3681
HIV Diagnosis and Treatment Market Introduction: FutureWise Market Research has instantiated a report that provides an intricate analysis of HIV Diagnosis and Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the HIV Diagnosis and Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the HIV Diagnosis and Treatment Market: • Viiv Healthcare Group of Companies, Inc. • Boehringer Ingelheim Gmbh • Bristol-Myers Squibb Company • Cipla Inc. • F. Hoffmann-La Roche Ltd • Gilead • Glaxosmithkline Plc. • Hologic Inc. • Viiv Healthcare Group of Companies, Inc. • Janssen Diagnostics • Johnson & Johnson Services • Merck & Co. Inc. • Mylan Inc. • Qiagen • Roche Diagnostics • Siemens Healthcare • Sysmex Corporation • Zyomyx Inc. • Partec • Pointcare Technologies Inc. (Note: The list of the major players will be updated with the latest market scenario and trends) HIV Diagnosis and Treatment Market Segmentation: By Test Type • Antibody Tests • Hiv-1 Screening Tests • Hiv-1 Antibody Confirmatory Tests • Hiv-2 & Group O Diagnostic Tests • Viral Identification Assays • Cd4 Testing • Viral Load Testing • Early Infant Diagnostics By Diagnostic Product • Assays, Kits & Reagents • Instruments • Software & Service • Others (Poc and Single Blood Drop Analyser) By Treatment • Protease Inhibitors (Pis) • Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis) • Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis) • Entry or Fusion Inhibitors • Integrase Inhibitors • Others By End User • Diagnostic Laboratories • Hospitals • Blood Banks • Home Care Settings • Other End Users By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the HIV Diagnosis and Treatment Market By Test Type, By Diagnostic Product, By Treatment, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Product Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of HIV Diagnosis and Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the HIV Diagnosis and Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the HIV Diagnosis and Treatment Market: • Viiv Healthcare Group of Companies, Inc. • Boehringer Ingelheim Gmbh • Bristol-Myers Squibb Company • Cipla Inc. • F. Hoffmann-La Roche Ltd • Gilead • Glaxosmithkline Plc. • Hologic Inc. • Viiv Healthcare Group of Companies, Inc. • Janssen Diagnostics • Johnson & Johnson Services • Merck & Co. Inc. • Mylan Inc. • Qiagen • Roche Diagnostics • Siemens Healthcare • Sysmex Corporation • Zyomyx Inc. • Partec • Pointcare Technologies Inc. (Note: The list of the major players will be updated with the latest market scenario and trends)
HIV Diagnosis and Treatment Market Segmentation: By Test Type • Antibody Tests • Hiv-1 Screening Tests • Hiv-1 Antibody Confirmatory Tests • Hiv-2 & Group O Diagnostic Tests • Viral Identification Assays • Cd4 Testing • Viral Load Testing • Early Infant Diagnostics By Diagnostic Product • Assays, Kits & Reagents • Instruments • Software & Service • Others (Poc and Single Blood Drop Analyser) By Treatment • Protease Inhibitors (Pis) • Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis) • Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis) • Entry or Fusion Inhibitors • Integrase Inhibitors • Others By End User • Diagnostic Laboratories • Hospitals • Blood Banks • Home Care Settings • Other End Users By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the HIV Diagnosis and Treatment Market By Test Type, By Diagnostic Product, By Treatment, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Product Type launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global HIV Diagnosis and Treatment Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of HIV Diagnosis and Treatment Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global HIV Diagnosis and Treatment Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global HIV Diagnosis and Treatment Market, By Test Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Antibody Tests 7.1.1. Hiv-1 Screening Tests 7.1.2. Hiv-1 Antibody Confirmatory Tests 7.1.3. Hiv-2 & Group O Diagnostic Tests 7.2. Viral Identification Assays 7.3. Cd4 Testing 7.4. Viral Load Testing 7.5. Early Infant Diagnostics 8. Global HIV Diagnosis and Treatment Market, By Diagnostic Product Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Assays, Kits & Reagents 8.2. Instruments 8.3. Software & Service 8.4. Others (Poc and Single Blood Drop Analyser) 9. Global HIV Diagnosis and Treatment Market, By Treatment Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Protease Inhibitors (Pis) 9.2. Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis) 9.3. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (Nrtis) 9.4. Entry or Fusion Inhibitors 9.5. Integrase Inhibitors 9.6. Others 10. Global HIV Diagnosis and Treatment Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Diagnostic Laboratories 10.2. Hospitals 10.3. Blood Banks 10.4. Home Care Settings 10.5. Other End Users 11. North America HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific HIV Diagnosis and Treatment Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Types Offered and Financial Layouts) 17.1. Viiv Healthcare Group of Companies, Inc. 17.1.1. Company Overview 17.1.2. Product Type Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Boehringer Ingelheim Gmbh 17.2.1. Company Overview 17.2.2. Product Type Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bristol-Myers Squibb Company 17.3.1. Company Overview 17.3.2. Product Type Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. PathoFinder BV 17.4.1. Company Overview 17.4.2. Product Type Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. F. Hoffmann-La Roche Ltd 17.5.1. Company Overview 17.5.2. Product Type Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Gilead 17.6.1. Company Overview 17.6.2. Product Type Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Glaxosmithkline Plc. 17.7.1. Company Overview 17.7.2. Product Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Hologic Inc. 17.8.1. Company Overview 17.8.2. Product Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Viiv Healthcare Group of Companies, Inc. 17.9.1. Company Overview 17.9.2. Product Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Janssen Diagnostics 17.10.1. Company Overview 17.10.2. Product Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11. Johnson & Johnson Services 17.11.1. Company Overview 17.11.2. Product Type Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12. Merck & Co. Inc. 17.12.1. Company Overview 17.12.2. Product Type Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13. Mylan Inc. 17.13.1. Company Overview 17.13.2. Product Type Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14. Qiagen 17.14.1. Company Overview 17.14.2. Product Type Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15. Roche Diagnostics 17.15.1. Company Overview 17.15.2. Product Type Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16. Partec 17.16.1. Company Overview 17.16.2. Product Type Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17. Pointcare Technologies Inc. 17.17.1. Company Overview 17.17.2. Product Type Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18. Siemens Healthcare 17.18.1. Company Overview 17.18.2. Product Type Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19. Sysmex Corporation 17.19.1. Company Overview 17.19.2. Product Type Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview 17.20. Zyomyx Inc. 17.20.1. Company Overview 17.20.2. Product Type Portfolio 17.20.3. SWOT Analysis 17.20.4. Financial Overview 17.20.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics